<DOC>
	<DOCNO>NCT00001858</DOCNO>
	<brief_summary>This protocol facilitate development method determine whether transplant recipient develop immune hyporesponsiveness tolerance towards allograft . These method involve study peripheral blood biopsy tissue obtain regular interval patient receive kidney combine kidney-pancreas allograft Warren G. Magnuson Clinical Center . In addition , patient previously receive kidney combine kidney-pancreas allograft evaluate use assay require peripheral blood mononuclear cell and/or biopsy . Assays develop protocol use subsequent protocol assess effect immune modulate treatment regimen may eventually use direct clinical care guide withdrawal immunosuppressive agent . However , patient enrol protocol change treatment base solely assays develop without enrol additional study .</brief_summary>
	<brief_title>Monitoring Tolerance Kidney Combined Kidney-Pancreas Transplants</brief_title>
	<detailed_description>This protocol facilitate development method determine whether transplant recipient develop immune hyporesponsiveness tolerance towards allograft . These method involve study peripheral blood biopsy tissue obtain regular interval patient receive kidney combine kidney-pancreas allograft Warren G. Magnuson Clinical Center . In addition , patient previously receive kidney combine kidney-pancreas allograft evaluate use assay require peripheral blood mononuclear cell and/or biopsy . Assays develop protocol use subsequent protocol assess effect immune modulate treatment regimen may eventually use direct clinical care guide withdrawal immunosuppressive agent . However , patient enrol protocol change treatment base solely assays develop without enrol additional study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>INCLUSION CRITERIA : Candidates kidney combine kidneypancreas transplant perform National Institutes Health , nonuremic healthy volunteer immunosuppressive medication . Previous recipient kidney combine kidneypancreas transplant . Recipients kidney combine kidneypancreas transplant interested participation Recurrent Disease Allograft Registry . Willingness legal ability give inform consent permission legal guardian . Willingness travel Clinical Center protocol specific sample take , case , ability send sample via overnight mail . For transplant patient , availability donor tissue test . This could include splenic peripheral blood lymphocyte cadaveric donor willing living donor enrol Clinical Center Living Donor Protocol consent periodic phlebotomy peripheral blood lymphocyte isolation . EXCLUSION CRITERIA : Inability unwillingness comply protocol monitoring therapy , include , among others , history noncompliance , circumstance compliance protocol requirement feasible due living condition , travel restriction , access urgent medical service , access antirejection drug research protocol complete . Any active malignancy . Patients primary , cutaneous basal cell squamous cell cancer may enrol provide appropriately eliminate prior transplant . Significant coagulopathy requirement anticoagulation therapy would contraindicate protocol allograft biopsy . Platelet count le 100,000/mm ( 3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 30, 2014</verification_date>
	<keyword>Biopsy</keyword>
	<keyword>Immune System</keyword>
	<keyword>Renal</keyword>
</DOC>